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Aims Cardiac myxomas usually develop in the atria and consist of an acid-mucopolysaccharide-rich myxoid matrix with
polygonal stromal cells scattered throughout. These human benign tumours are a valuable research model because
of the rarity of cardiac tumours, their clinical presentation and uncertain origin. Here, we assessed whether multi-




Twenty-three myxomas were collected and analysed for the presence of multipotent CSCs. We detected myxoma
cells positive for c-kit (c-kitpos) but very rare Isl-1 positive cells. Most of the c-kitpos cells were blood lineage-
committed CD45pos/CD31pos cells. However, c-kitpos/CD45neg/CD31neg cardiac myxoma cells expressed stemness
and cardiac progenitor cell transcription factors. Approximately <_10% of the c-kitpos/CD45neg/CD31neg myxoma
cells also expressed calretinin, a characteristic of myxoma stromal cells. In vitro, the c-kitpos/CD45neg/CD31neg myx-
oma cells secrete chondroitin-6-sulfate and hyaluronic acid, which are the main components of gelatinous myxoma
matrix in vivo. In vitro, c-kitpos/CD45neg/CD31neg myxoma cells have stem cell properties being clonogenic, self-
renewing, and sphere forming while exhibiting an abortive cardiac differentiation potential. Myxoma-derived CSCs
possess a mRNA and microRNA transcriptome overall similar to normal myocardium-derived c-kitpos/CD45neg/
CD31negCSCs , yet showing a relatively small and relevant fraction of dysregulated mRNA/miRNAs (miR-126-3p
and miR-335-5p, in particular). Importantly, myxoma-derived CSCs but not normal myocardium-derived CSCs,
seed human myxoma tumours in xenograft’s in immunodeficient NOD/SCID mice.
...................................................................................................................................................................................................
Conclusion Myxoma-derived c-kitpos/CD45neg/CD31neg CSCs fulfill the criteria expected of atrial myxoma-initiating stem cells.
The transcriptome of these cells indicates that they belong to or are derived from the same lineage as the atrial
multipotent c-kitpos/CD45neg/CD31neg CSCs. Taken together the data presented here suggest that human myxo-
mas could be the first-described CSC-related human heart disease.
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Introduction
Primary tumours of the heart are rare, with an incidence between
0.0017% and 0.19% in unselected patients at autopsy.1–3 Three quar-
ters of the tumours are benign and nearly half the benign heart
tumours are myxomas. Myxoma has an annual incidence of 0.5 per
million people and most commonly presents in 30- to 50-year-old
adults4 with a slight preponderance in women (65%).Cardiac myxo-
mas are typically sporadic and isolated, while only in 5–10% are famil-
ial5 and usually develop in the atria (75% from the left atrium and 18%
from the right atrium)6 and they are regarded as benign neoplasms in
the histological conventional sense. However, the oncologic designa-
tion of benignity understates the potentially devastating effect this tu-
mour may have on the patient. By virtue of their location, cardiac
myxomas can produce myriad clinical manifestations, sometimes
with fatal consequences, such as heart failure and distant
embolisms of the CNS or other organs depending on their location.
Therefore, these benign tumours, despite their rarity, continue to
generate interest because of their clinical presentation and uncertain
histogenesis.
A myxoma consists of a myxoid stroma rich in acid-
mucopolysaccharide with polygonal cells scattered throughout.
Differentiation of myxoma cells towards neuronal, smooth muscle,
endothelial, fibroblasts, and myocytes along with typical stromal cells
has been described.7–9 The pathogenesis of cardiac myxoma is poorly
understood with early debates about whether cardiac myxomas
were, indeed, neoplastic entities or organized thrombus. Recent gene
expression and immunohistochemical studies have postulated that
cardiac myxomas are neoplasms with the tumour cells arising most
likely from multipotent mesenchymal cells yet to be identified.10–12
Many studies have shown that the prototypical stem-cell properties
(self-renewal, clonogenicity, and multipotent differentiation ability)
are relevant to some forms of cancer.13,14 Biologically distinct and
relatively rare populations of ‘tumour-initiating’ cells have been iden-
tified in different form of cancers which have properties closely paral-
lel to the three features that define normal stem cells. Malignant cells
with these functional properties have been termed ‘cancer stem cells’
(CaSCs).
Although previously considered to be a terminally differentiated
organ, the adult mammalian heart has been shown to have the ability
to develop new cardiomyocytes and microvasculature throughout
life.15 Although the extent and biological significance of this cell-
renewal capacity remains controversial,16–18 it has been demon-
strated that the adult mammalian heart harbours a population of
bona fide resident endogenous cardiac stem/progenitor cells (CSCs).
Such cells have been identified by us and other groups in a range of
different mammalian species, including human. The CSCs were first
characterized by expression of c-kit (also known as CD117), the kin-
ase receptor for stem cell factor.19,20 However, the adult heart con-
tains a heterogeneous c-kitpos cell population most of which display
blood and endothelial lineage-commitment.21–23 The c-kitpos/
CD45pos population shows mast cells identity, while c-kitpos/
CD31pos are endothelial (precursor) cells.22,24,25 Recently, it was
demonstrated that only a small fraction of c-kitpos cardiac cells, nega-
tive for CD45 and CD31, are enriched for multipotent CSCs.21
These cells are distributed throughout the myocardium with the
highest density in the atria and apex.19,26
Based on the above, the objectives of this study were to assess
whether c-kitpos/CD45neg/CD31neg cardiac cells contribute to car-
diac myxoma histogenesis and whether myxoma-derived c-kitpos/
CD45neg/CD31neg cells exhibit, in vitro and in vivo, the properties of
myxoma stem cells.
Translational perspective
Primary tumours of the heart are rare, and among them, the vast majority is represented by cardiac myxomas. The typical cardiac myxoma is
regarded as a benign neoplasm in a conventional sense. However, the oncologic designation of benignity understates the potentially clinical
devastating effect this cardiac tumour may impose on the patient. Therefore, these benign tumours, despite their rarity, continue to generate
interest because of their clinical presentation and uncertain histogenesis. The pathogenesis of cardiac myxoma is indeed poorly understood.
Although there was debate in the past about whether cardiac myxoma was a neoplastic entity or an organized thrombus, recent gene expres-
sion and immunohistochemical studies established that cardiac myxoma is a neoplasm postulating that tumour cells arise most likely from mul-
tipotent mesenchymal cells, yet to be identified. Here, assessing 23 human cardiac myxomas, we detected within myxoma tissue c-kitpos/
CD45neg/CD31neg cardiac cells expressing stemness and cardiac progenitor cell transcription factors. Some (<10%) of these c-kitpos/CD45neg/
CD31neg cardiac myxoma cells expressed also calretinin, likely representing myxoma stromal precursor cells. More importantly, c-kitpos/
CD45neg/CD31neg cardiac myxoma cells secrete the typical gelatinous matrix of cardiac myxoma. These c-kitpos/CD45neg/CD31neg cardiac
myxoma cells show stem cell properties being clonogenic, self-renewing, and sphere forming. The myxoma-derived multipotent cells exhibit a
transcriptome and miRNA network which is similar to that of the cardiac stem/progenitor cells (CSCs) from normal myocardium but with a
relatively small fraction of dysregulated mRNAs and miRNAs (and miR-126-3p and miR-335-5p, in particular) involved in cell growth, differen-
tiation and transformation pathways. Importantly, myxoma-derived multipotent CSCs seed human myxoma tumour in xenograft’s experi-
ments in immunodeficient mice. Therefore, for the first time, we provide the evidence of the existence of a tissue-specific myxoma-initiating
stem cell in atrial myxoma. Accordingly, cardiac myxomas appear to be the first CSC-related human cardiac disease.































































































Detailed description of the methods is in the Supplementary material on-
line, Methods. The authors declare that all data supporting the findings of
this study are available either within the article or from the corresponding
author on reasonable request.
Results
c-kitpos/CD45neg/CD31neg cells are
present within atrial myxomas and
express stemness and cardiac
transcription factors
Twenty-three cardiac imaging-identified myxoma tumours
(Supplementary material online, Table S1) were surgically excised and
processed for histology and immunohistochemistry analysis. All the
tumours exhibited the typical histological cellular and extracellular
matrix features of cardiac atrial myxoma (Supplementary material
online, Figure S1). Dispersed within the myxoma matrix, we detected
cells expressing known embryonic and adult cardiac stem/progenitor
markers such as c-kit, the receptor of the stem cell factor (Figure 1A).
Total c-kitpos cardiac cells number was higher in the myxoma tissue
than in the normal atrial tissue obtained from control patients
(n = 10) (Figure 1B). The significance, if any, of this difference in c-kitpos
cells density is doubtful considering the differences in tissue
composition.
We have already reported that c-kit expression in the adult myo-
cardial cells mainly identifies endothelial and mast cells.21
Accordingly, most of the myxoma c-kitpos cells were CD45pos or
CD31pos (85 ± 5%) (Figure 1B–D), representing either cardiac mast
cells and/or endothelial cells, respectively. Moreover, myxoma c-kit-
pos/CD45pos cells were also tryptasepos, confirming their mast cell
phenotype (Figure 1C). A similar fraction of c-kitpos/CD45pos/
CD31pos cells (83 ± 7%) within the total cardiac c-kitpos cells was
detected in the normal right atrial tissue of the controls (Figure 1B).
On the other hand, we also identified c-kitpos cardiac myxoma cells
that were negative for both CD45 and CD31 (Figure 1E). In the adult
mammalian heart, c-kitpos/CD45neg/CD31neg cells are highly enriched
for CSCs.19,21,24 Immunofluorescent staining revealed that c-kitpos/
CD45neg/CD31neg myxoma cells co-express several stemness and
cardiac progenitor cell transcription factors, such as Oct-4, Nkx2.5,
and Isl-1 in different percentages (Figure 1F–I), markers known to be
also expressed in normal c-kitpos/CD45neg/CD31neg CSCs from
healthy human atrial tissue.23,27
Overall, these data raise the question of whether the c-kitpos/
CD45neg/CD31neg myxoma cells are derived from the atrial c-kitpos/
CD45neg/CD31neg stem/precursor cells and whether they are myx-
oma multipotent stem/progenitor cells.
Evidence of intermediate cell phenotype
between undifferentiated cardiac
progenitor cells and polygonal stromal
myxoma cells
The cellular compartment of myxomas is composed of stromal cells
which mainly have a polygonal structure. These cells, also known as
leipidic cells, exhibit molecular and phenotypic traits of multiple cell
types, such as neuronal, endothelial, vascular, and cardiac cells.7,28,29
One of the salient characteristics of cancer stem cells (CaSCs) is that
they give rise to the non-CaSCs-cells within a tumour which display a
more differentiated phenotype and have less proliferative capacity
compared to the CaSCs. Differentiated cells within the tumour mass
are believed to be the product of the progressive abortive differenti-
ation of undifferentiated CaSCs, which involves the formation of cell
intermediates constituting the cellular heterogeneity of some neopla-
sias.30 Thus, we searched for c-kitpos/CD45neg/CD31neg myxoma
cells expressing myxoma cell markers.
Different markers have been used to specifically identify polygonal
cells.31 Recently, calretinin has been shown to mark the majority of
myxoma cells.32 Most of the myxoma polygonal cells in the myxomas
reported here were positive for calretinin (74 ± 7%, Figure 1J).
Importantly, 10± 3% of the c-kitpos/CD45neg/CD31neg myxoma cell
cohort expressed calretinin (Figure1K and L). In contrast, calretinin
was not expressed in c-kitpos CSCs from normal atrial tissue. Thus,
the presence c-kitpos/CD45neg/CD31neg/calretininpos cells within
myxoma tissue appears to identify myxoma stromal precursor cells.
This concordance potentially links the multipotent c-kitpos/CD45neg/
CD31neg CSCs present in the normal adult myocardium with the c-
kitpos/CD45neg/CD31neg/calretininpos myxoma cells which are likely
the precursors of the myxoma leipidic cells.
Myxoma-derived c-kitpos/CD45neg/
CD31neg cells are clonogenic and
spherogenic with an abortive cardiac
differentiation potential
To assess the stem cell properties of putative multipotent myxoma
stem cells,33 we processed the six most recently excised out of the
23 myxomas and disaggregated them to single cells by enzymatic di-
gestion. FACS analysis confirmed that c-kitpos cells were about
11 ± 3% of all nucleated cells the myxoma (Figure 2A). Most of these
c-kitpos cells co-expressed CD45 and CD31 (Figure 2A), confirming
the immunohistochemistry data (Figure 1C and D). Through MACS
sorting we obtained c-kitpos/CD45neg/CD31neg myxoma cells and
compared their cellular properties in vitro to normal human CSCs
similarly isolated from three right atrial appendix tissues.
Normal human CSCs are efficiently clonogenic. At passage 8 (P8),
they clone (Figure 2B) with an efficiency of 13 ± 4% (Figure 2C). A typ-
ical clone of normal hCSCs has been expanded more than 50 pas-
sages so far. After these passages, these cells retain telomerase
activity and normal telomere length, without cellular and/or molecu-
lar evidence of senescence (Supplementary material online, Figure
S2A). Clonogenic normal hCSCs express mRNA and protein of rec-
ognized ‘stemness’ and cardiac progenitor genes such as C-KIT, MDR-
1, OCT-4, NANOG, BMI-1, TERT, GATA-4, and NKX2.5 (Supplementary
material online, Figure S2B and C). The expression of genes like CD34
and CD45 is faintly detected if not practically negative
(Supplementary material online, Figure S2B). A multimarker expres-
sion profile by flow cytometry of clonogenic normal human c-kitpos/
CD45neg/CD31neg CSCs shows that the membrane phenotype of
these cells is positive for: CD166, CD90, CD81, CD105, CD44,
CD9, CD63, CXCR4, MDR-1, E-CADHERIN, PDGFRa, and negative
for: CD45, CD31, CD34, and CD150 (Supplementary material
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Figure 1 c-kit expression identifies putative multipotent resident cardiac stem cells within myxoma. (A) Representative confocal microscopy image
of c-kitpos cells within the myxoid matrix of a myxoma tumour (c-kit/green fluorescence, chondroitin sulfate/red, nuclei/DAPI/blue). Scale bar =
50lm. (B) Percentage of total c-kitpos cardiac cells and c-kitpos/CD45pos/CD31pos cardiac cells in normal control (right atria) tissue and in myxoma tu-
mour tissue. (C) Representative confocal microscopy image showing that most of the myxoma c-kitpos cells were also CD45pos/Tryptasepos (c-kit/
green, CD45/red, Tryptase/white, nuclei/blue) or (D) CD31pos (c-kit/green, CD31/red, nuclei/DAPI/blue). Scale bar = 50 lm. (E) Representative con-
focal microscopy image show that despite the majority of c-kitpos cells are CD45pos/CD31pos, few of the c-kitpos cells are CD45neg/CD31neg (white
arrow) in myxoma tissue. Scale bar = 50 lm. (F–H) Representative confocal microscopy images of c-kitpos myxoma cells dispersed within myxoid
matrix (chondroitin sulfate/red), which express stemness and cardiac progenitor cell transcription factors and respectively Oct-4 (white), Nkx2.5
(white), and Isl-1 (white). Scale bar = 50 lm. (I) Bar graph showing the quantification of the number of c-kitpos/CD45neg/CD31neg cardiac cells, c-kit-
pos/CD45neg/CD31neg/Oct-4pos, c-kitpos/CD45neg/CD31neg/Nkx2.5pos, c-kitpos/CD45neg/CD31neg/Isl-1pos, c-kitneg/Oct-4pos, and c-kitneg/Isl-1pos car-
diac cells within myxoma tumour. (J–L) Representative confocal microscopy images showing the presence of the common myxoma tumour cell
marker, Calretinin, dispersed in abundant myxoid matrix (J). Importantly, some of calretininpos cells are also c-kitpos but CD45neg/CD31neg (c-kit/
green, CD45-CD31/red, calretinin/white, nuclei/DAPI/blue), which potentially identify myxoma stromal precursor cells (K, L). Scale bar =50 lm in J,
K, and 20 lm in L. Data are presented as mean ± SD (n = 23 for myxoma and n = 10 for human controls).
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Figure 2 Identification, expansion/clonogenic potential and phenotipic characterization of myxoma-derived c-kitpos/CD45neg/CD31neg cells in vitro.
(A) Flow cytometry dot plots showing the percentage of total c-kitpos, c-kitpos/CD31pos, and c-kitpos/CD45pos cardiac cells population within myxoma
cells isolated from myxoma tissue (representative of n = 6 experiments). (B) Representative light microscopy images of a c-kitpos/CD45neg/CD31neg
hCSC clone (right) obtained depositing a single c-kitpos/CD45neg/CD31neg hCSC (left) into 96-well Terasaki plates. Scale bar = 400 lm. (C) Graph
showing the clonogenic capacity of myxoma-derived c-kitpos/CD45neg/CD31negCSCs compared to normal hCSCs at P8 (representative of n = 6 bio-
logical replicates). (D) Cellular growth curve in vitro shows the growth deficit of c-kitpos/CD45neg/CD31neg myxoma-derived CSCs compared to c-kit-
pos/CD45neg/CD31neg hCSCs at P12. P < 0.05 vs. c-kitpos/CD45neg/CD31neg hCSCs (representative of n = 6 biological replicates). (E) Flow cytometry
dot plots showing the phenotypic characterization of c-kitpos/CD45neg/CD31neg myxoma-derived ‘putative’ CSCs. Data are presented as mean ± SD.






























































































online, Figure S2D). When grown in suspension, normal hCSCs are
multipotent and give rise to pseudoembryoid bodies, also known as
cardiospheres (Supplementary material online, Figure S3A). When
grown in specific conditioned differentiation media, normal hCSCs
differentiate into cardiomyocytes, vascular smooth muscle, and endo-
thelial cells in vitro (Supplementary material online, Figure S3B and C).
c-kitpos/CD45neg/CD31neg cardiac myxoma-derived cells (hereafter
referred to also as myxoma-derived ‘putative’ CSCs) at P8 show a clo-
nogenic capacity similar to normal hCSCs, 11± 2% (Figure 2C).
However, at P12 the myxoma cells start to show a significant prolonga-
tion of their doubling time (Figure 2D) with reaches practical growth ar-
rest at P16. This cell growth deficit was associated with a significant
increase in spontaneous apoptotic cell death as revealed by TdT assay
[0.1 ± 0.1% TdTpos cells in normal hCSCs compared to 5 ± 3% in c-
kitpos myxoma cells at P16 (P < 0.01)]. Moreover, at P12 c-kitpos/
CD45neg/CD31neg myxoma-derived CSCs become larger with a diam-
eter of 15 ± 2lm when compared with 10 ± 2lm of normal human
eCSCs (P < 0.01). Interestingly, c-kitpos/CD45neg/CD31neg myxoma-
derived CSCs at P12 can still be cloned with an efficiency of 8 ± 2%.
Cloned c-kitpos/CD45neg/CD31neg myxoma-derived CSCs express
a membrane multimarker profile (Figure 2E) very similar to normal
human c-kitpos/CD45neg/CD31neg CSCs (Supplementary material on-
line, Figure S2C). Also, these clonogenic c-kitpos/CD45neg/CD31neg
myxoma-derived CSCs express OCT-4, NANOG, BMI-1, NKX2.5, and
ISL-1 (Figure 3A) and form cardiospheres at a rate similar to normal
human CSCs even though serial spherogenesis was reduced
(Figure 3B and Supplementary material online, Figure S3A). When
grown in specified endothelial differentiation media, clonogenic c-kit-
pos/CD45neg/CD31neg myxoma-derived CSCs up-regulated endothe-
lial lineage-restricted genes similarly to hCSCs (Figure 3C and
Supplementary material online, Figure S3B). However, in smooth
muscle cell (SMC) differentiation media, the expression of SMC lin-
eage markers was lower in differentiated c-kitpos/CD45neg/CD31neg
myxoma-derived CSCs compared to normal human c-kitpos/
CD45neg/CD31neg CSCs (Figure 3D and Supplementary material on-
line, Figure S3B). More importantly, when clonogenic c-kitpos/
CD45neg/CD31neg myxoma-derived CSCs are primed for cardio-
myogenic differentiation, they up-regulated cardiac myocyte tran-
scription factors but in vitro they fail to express significant levels of the
contractile cardiac muscle genes , in contrast to normal hCSCs
(Figure 3E and Supplementary material online, Figure S3C).
Overall, these data show that c-kitpos/CD45neg/CD31neg myxoma-
derived CSCs have many similarities with the normal myocardium-
resident c-kitpos/CD45neg/CD31neg CSCs and fulfill the in vitro criteria
for myxoma tumour stem cells: they are clonogenic, self-renewing,
and multipotent, yet they accumulate a growth deficit over passages,
which is consistent with the typical low proliferation index of cardiac
myxomas.10,34 In addition, they show a biased differentiation potential
towards endothelial cells while they exhibit an abortive myogenic dif-
ferentiation potential, which is also typical of myxoma tissue.14
c-kitpos/CD45neg/CD31neg myxoma-
derived CSCs produce the typical myxoid
matrix
The abundant gelatinous matrix is the most impressive aspect of
the morphologic appearance of cardiac myxomas.35–37 This
gelatinous matrix consist of glycosaminoglycans related to chon-
droitin sulfates and hyaluronic acid which are produced by the
myxoma cells.35–37
Thus, we analysed and measured glycosaminoglycan content and
production of myxoma-derived c-kitpos/CD45neg/CD31neg CSCs at
P8-12 by HPLC. Chondroitin-6-sulfate and hyaluronic acid, the main
disaccharide units of glycosaminoglycans composing the gelatinous
matrix,37 were particularly abundant in the glycosaminoglycan pro-
duced and secreted by myxoma-derived c-kitpos/CD45neg/CD31neg
CSCs (Figure 3F) and were the most prevalent in the culture medium
analysed (Figure 3G).
These data further show that myxoma-derived c-kitpos/CD45neg/
CD31neg CSCs behave and show the characteristics expected from
myxoma tumour stem cells.
RNASeq analysis reveals significant
similarities and differences in the
transcriptome of c-kitpos/CD45neg/
CD31neg myxoma-derived CSCs and
normal c-kitpos/CD45neg/CD31neg CSCs
To assess the gene expression similarities and differences be-
tween the myxoma-derived ‘putative’ CSCs and normal human
CSCs, we analysed the RNA expression profile of these two-cell
populations (n = 6 clones from 2 myxoma patients and n = 9
clones from 3 control human patients) by RNASeq analysis. To in-
crease the significance of this mRNA profile analysis, only mRNAs
that had a read counts >_100 and a [fold change] >_1.5 were consid-
ered. A total of 15 321 mRNAs were analysed in this comparison
and 1243 were differentially expressed in the two cell types (see
Supplementary material online, Table S2). That the myxoma-
derived CSCs share 90% of gene expression with human CSCs
highly point to a common origin for these cells. On the other
hand, of the differentially regulated genes, 407 mRNA were signifi-
cantly up-regulated (>_1.5 fold difference) and 836 were down-
regulated (-1.5 fold difference) in myxoma-derived c-kitpos/
CD45neg/CD31neg CSCs vs. normal c-kitpos/CD45neg/CD31neg
CSCs (Figure 4A and Supplementary material online, Table S2).
Subsequently, we assessed the dysregulated mRNAs by bioinfor-
matic Ingenuity pathway’s analysis (IPA) to identify the specific mo-
lecular processes affected by these mRNAs. The dysregulated
mRNAs were specifically involved with apoptosis signalling, cell cycle
checkpoints, factors promoting cardiogenesis, stem cell pluripotency,
inhibition of matrix metalloproteases, molecular mechanism of can-
cer, tissue factor in cancer, and telomerase signalling (Figure 4B and
Supplementary material online, Table S2). Furthermore, IPA further
revealed that the dysregulated genes in myxoma-derived CSCs are
components of several canonical pathways (Figure 4C) such as HGF
and IGF-1 signalling, telomerase signalling, stem cell pluripotency, and
stem cell signalling among others (Figure 4C). Also, these dysregulated
mRNAs are involved with several specific biological functions
(Figure 4C), such as organ development, cell signalling, and post-
translational modification, cardiovascular disease, DNA replication,
recombination and repair, cell cycle, and cancer among several
others (Figure 4C).
In summary, the RNASeq analysis clearly shows that the myx-
oma-derived ‘putative’ CSCs and the normal human CSCs are
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Figure 3 c-kitpos/CD45neg/CD31neg myxoma-derived ‘putative’ CSCs show multilineage differentiation and myxoid matrix production potential
in vitro. (A) Representative confocal microscopy images obtained from cytospin preparations of c-kitpos/CD45neg/CD31neg myxoma-derived CSCs
revealed the expression of stemness and cardiac progenitor markers. c-kit (green), Oct-4, Nanog, Bmi-1, Nkx2.5, and Isl-1 (red) (representative of n
= 6 biological replicates). Scale bar = 50 lm. (B) Representative light microscopy image of primary (top panel) and tertiary cardiospheres (bottom
panel) derived from c-kitpos/CD45neg/CD31neg myxoma CSCs. The number of tertiary cardiospheres is reduced in c-kitpos/CD45neg/CD31neg myx-
oma-derived CSCs (representative of n = 6 biological replicates). Scale bar = 100 lm. (C) qRT-PCR data (upper panel) showing the expression levels
of the main endothelial differentiation genes (CD31and vWf) in normal and myxoma-derived c-kitpos/CD45neg/CD31neg CSCs at baseline (0 day) or
after 14 days in endothelial differentiation media and representative confocal microscopy images (bottom panel) showing the expression of vWF in
c-kitpos/CD45neg/CD31neg myxoma-derived CSCs at 14 days after endothelial differentiation (vWf, green; nuclei/blue). Scale bar = 100 lm. (D) qRT-
PCR data (upper panel) showing the expression levels of the main smooth muscle differentiation genes (ACTA2 and MYH11) in normal and myxoma-
derived c-kitpos/CD45neg/CD31neg CSCs at baseline (0 day) or after 14 days in smooth muscle differentiation media and representative confocal mi-
croscopy images (bottom panel) showing the expression of smooth muscle actin (SMA) in c-kitpos/CD45neg/CD31neg myxoma CSCs at 14 days after
smooth muscle differentiation (SMA, green; nuclei/DAPI/blue) P < 0.05 vs. 0 day. Scale bar = 100 lm. (E) Heat maps (upper panel) showing qRT-
PCR analysis of C-KIT, GATA-4, NKX2.5, and TNNT2 gene transcripts in differentiating c-kitpos/CD45neg/CD31neg hCSCs when compared with c-kitpos/
CD45neg/CD31neg myxoma-derived CSCs at different time points. Colour scale indicates change in Ct (threshold cycle) relative to the normalized
GAPDH control. A representative confocal microscopy image (bottom panel) shows very few MF20pos (green) cardiomyogenic-committed cells in
differentiated ckitpos/CD45neg/CD31neg myxoma CSC-derived Cardiospheres 14 days after cardiomyogenic differentiation. Scale bar = 100 lm (rep-
resentative of n = 6 biological replicates). (C–E, representative of n = 6 biological replicates). (F, G) Bar graph showing the glicosaminoglycans compos-
ition of c-kitpos/CD45neg/CD31neg myxoma-derived CSCs and in the culture media of c-kitpos/CD45neg/CD31neg myxoma-derived CSCs as obtained
by HPLC analysis (representative of n = 6 biological replicates). Data are presented as mean ± SD.














..closely related and, most likely, the former are derived from the
latter. In addition, the RNASeq data uncovered specific gene ex-
pression changes in myxoma-derived CSCs which are consistent
with the cellular phenotype of myxoma tumours, with their abort-
ive neuronal/cardiac differentiation and the hyperproduction of
proteoglycans forming the prototypical myxoma gelatinous ma-
trix. Taken together the phenotype and gene expression profile of
the ‘myxoma-derived CSCs’, compared to the CSCs from normal
myocardium, strongly points to them as the stem cells of cardiac
myxoma.
Figure 4 Myxoma-derived CSCs show significant and specific differences of their transcriptome when compared with control human CSCs. (A)
Heatmaps showing the expression values, as log2 of normalized read-counts (left) and fold-change (FC, right) of RNAs by RNASeq analysis of hCSCs
and myxoma-derived (Myx)CSCs. Only RNAs with jFCj>_3 and FDR <_0.05 are represented. (B) Heatmaps showing the expression values (left) and
FC of RNAs involved in selected biological functions (P-value <_ 0.05) as computed by IPA in the comparison of hCSCs vs. MyxCSCs. (C) (Upper
panel) Histogram showing the canonical pathways statistically significant (P-value <_ 0.05), as defined by IPA, involving RNAs differentially expressed in
the comparison of hCSCs vs. MyxCSCs. (Bottom panel) Histogram showing the biological functions statistically significant, as defined by IPA, involving
RNAs differentially expressed in the comparison of hCSCs vs. MyxCSCs.



















microRNA profile of myxoma-derived
c-kitpos/CD45neg/CD31neg CSCs
MicroRNAs (miRNA), small non-coding RNAs that play critical roles
in normal stem cell functions in development, adult homeostasis and
disease, have emerged as important regulators of tumours and cancer
stem cells.38 Very little is yet known about microRNA regulation in
the biology of adult human CSCs either in vitro and in vivo. Therefore,
we assessed the microRNA expression profile in myxoma-derived
c-kitpos/CD45neg/CD31neg CSCs to identify miRNA/mRNA net-
works potentially involved in their above-described gene expres-
sion dysregulation when compared to normal human CSCs.
MicroRNA profile was obtained by RNASeq from the same sam-
ples used for the mRNA transcriptome analysis above. To increase
the significance of the whole miRNA profile analysis, only miRNAs
Figure 5 MicroRNA profile of myxoma-derived CSCs. (A) Heatmaps showing the expression values, expressed as log2 of normalized read-counts
(left) and fold-change (right) of miRNAs by RNASeq analysis of hCSCs vs. MyxCSCs. Only miRNAs with jFCj >_ 2 and FDR <_0.05 are represented.
(B) Boxplots showing the log2 normalized expression read counts of selected miRNAs in hCSCs and MyxCSCs samples. (C) miRNAs-mRNAs targets
networks. In green are shown down-regulated miRNAs and respective regulated target mRNAs, while in red are shown up-regulated miRNAs and
respective modulated target mRNAs. (D) Histograms showing the pathways where mRNA targets of selected miRNAs are involved (left) and the fre-
quency of miRNAs down-regulated/mRNAs target up-regulated involved in that specific pathway in myxCSCs. (E) Network representation of specif-
ic biological functions where selected miRNAs/mRNA targets are involved in myxCSCs.






























































































that show a read count >_90 and a [fold-change] >_1.5 were consid-
ered. On this basis, we detected 66 microRNA differently regulated
in the comparison. Specifically, 38 miRNA up-regulated and 28 down-
regulated in myxoma-derived CSCs vs. normal human CSCs
(Figure 5A and Supplementary material online, Table S3). miR-138-5p is
the most down-regulated in myxoma-derived CSCs (Figure 5B and
Supplementary material online, Table S3). Down-regulation of miR-
138 is observed in a variety of cancer types, which suggests that it may
be involved in their pathogenesis.39,40 miR-335 was also significantly
down-regulated in myxoma c-kitpos cells (Figure 5B and
Supplementary material online, Table S3). Interestingly, miR-335 is
encoded in the mesoderm-specific transcript (Mest) which is signifi-
cantly modulated during the differentiation of embryonic stem cells to
mesodermal cardiomyocyte precursors41 and it is considered a po-
tential tumour suppressor in many cancer types.38 Furthermore, miR-
355 regulates the expression of extracellular matrix components.41,42
On the other hand, miR-126 is the most up-regulated in the myx-
oma-derived CSCs (Figure 5B and Supplementary material online,
Table S3). This miR mainly contributes to normal vascular develop-
ment during embryogenesis and to the regenerative function of
haematopoietic stem cells.43–45 Recently, it has been reported that
higher expression of miR-126 accelerates cancer progression by acti-
vation of mitogen-activated protein kinase and Akt, while it also sup-
presses tumour proliferation and tissue invasion by decreasing Crk
expression. These contradictory actions suggest that miR-126 has
several alternative functions specific to the type of malignancy.46
We specifically scanned for the known and potential mRNA tar-
gets of each down- and up-regulated miRNAs through IPA
‘microRNA Target Filter’ using ‘TargetScan Human’ and ‘TarBase’.
The up-regulated mRNA putative targets of the down-regulated
microRNAs in myxoma vs. normal CSCs and vice versa to generate
the miR/mRNA networks of the two cell types (Figure 5C). The bio-
informatic analysis revealed that the miRNA/mRNA network de-
regulated in myxoma-derived CSCs fall into six main categories: pro-
teoglycans in cancer, cGMP-PKG signalling pathway, Ras signalling
pathway, biosynthesis of amino-acids, apoptosis of tumour cells, and
cell cycle progression (Figure 5D and E).
Overall, the un-biased RNASeq and bioinformatics analysis of the
differentially regulated miRNA networks revealed that myxoma-
derived CSCs (myxoma putative stem cells) have a gene expression
and regulatory microRNAs profile that is consistent and concordant
with the cellular features exhibited by these cells in vitro and in vivo.
Therefore, these mRNA/miRNA networks have the potential to be-
come an entry point to unravel the main molecular mechanisms
underlying the myxomatous transformation and to further ascertain
the causative role of CSCs in its genesis.
miR-126-3p and miR-335-5p regulate the
biology of myxoma-derived CSCs in vitro
On the basis of the RNASeq-based miR-nome data above, we have
then evaluated the effects of the five dysregulated miRs (Figure 5B) on
growth, clonogenic and myogenic potential of myxoma-derived CSCs
(n=3) through selective gain and loss of function experiments based on
the infection of lentiviral particles to transduce green fluorescent pro-
tein (GFP) together with a specific miRNA mimic or inhibitor (and a
puromycin resistance cassette). At 50 MOI, we infected a large
majority of myxoma-derived CSCs and with a single dose of puromycin
we reached over 90% of GFP expressing cells from each specific miR-
mimic and -inhibitor (Supplementary material online, Figure S4A).
Forty-eight hours after lentiviral infection, we accordingly obtained sig-
nificant overexpression of the relative miR-mimic (Supplementary ma-
terial online, Figure S4B). More importantly, cell growth analysis of
myxoma-derived CSCs shows that out of the five different miR stable
overexpression or suppression, miR-126-3p inhibition was the only
treatment able to rescue myxoma-derived CSCs cell growth retard-
ation at P12 (Figure 6A). Indeed, miR-126-3p-suppressed myxoma-
derived CSCs had a significant higher growth kinetics when compared
with control Lenti-GFP infected and transduced cells (Figure 6B).
Accordingly, clonal efficiency analysis by single-cell deposition show
that miR-126-3p-inhibited myxoma-derived CSCs has higher clono-
genic capacity when compared with control Lenti-GFP infected and
transduced cells (Figure 6C). Of interest, mRNA Seq analysis of
myxoma-derived cells show that miR-126-3p up-regulation in these
cells when compared with normal hCSCs is associated with specular
down-regulation of several genes involved with cell cycle/growth and
in particular of plexin-B2 (PLXNB2) (Supplementary material online,
Figure S4C), which has been recently shown to play a key role in
growth, survival and regenerative capabilities of normal haematopoietic
and leukaemic stem and progenitor cells.47
On the other hand, miR-335-5p inhibition was the only miR-
modulating lentiviral infection that fostered robust myxoma-derived
CSC myogenic commitment (Figure 6D). Indeed, while miR-126-3p
inhibition and miR-138 up-regulation resulted in the up-regulation of
single myogenic genes (Figure 6D and Supplementary material online,
Figure S4D), miR-335-inhibitor treated myxoma-derived CSCs show
a coherent and significant up-regulation of the main cardiac transcrip-
tion factors (GATA-4, MEF2C and NKX2.5,) ensuing to an up-
regulation of the main contractile genes (MYH6, MYH7, TNNT2, and
ACTC1) in vitro upon 14 days in myogenic differentiation media (Figure
6D, E ). miR-335-5p was found down-regulated in unprimed cultured
myxoma-derived CSCs when compared with human CSCs (see
Figure 5B). Thus, miR-335-5p modulation could explain at least in part
the abortive myogenic differentiation of myxoma cells. On the other
hand, completely blocking miR-335-5p by a specific inhibitor could be
a potential cardio-regenerative compound to enhance new myocyte
formation from stem and progenitor cells and it remains mandatory
to evaluate in future works the actual molecular target(s) that miR-
335-p suppresses to regulate cardiomyogenic specification.
c-kitpos/CD45neg/CD31neg myxoma-
derived CSCs seed myxoma tumours
in vivo
Cancer-initiating (tumourigenic) cells typically form tumours after
transplantation into NOD/SCID immunodeficient mice.48 To assess
the potential of myxoma-derived c-kitpos/CD45neg/CD31neg CSCs to
seed cardiac myxomas in vivo, we transplanted 104 to 106 myxoma-
derived CSCs (engineered to express green fluorescent protein by
lentiviral transduction), isolated from three different patients,
through intramuscular injection into the quadriceps muscle of 27
NOD-SCID immunodeficient mice (Figure 7A). Normal hCSCs (also
GFP labelled) isolated from three different atrial specimens were
used as controls and similarly transplanted (Figure 7A).
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Figure 6 miR-126-3p and miR-335-5p dictate, respectively, the expansion/clonogenic deficit and the abortive myogenic differentiation potential of
clonogenic myxoma-derived CSCs in vitro. (A) Cellular growth curve in vitro shows the effects of the different modulated (up-regulated by the relative
miR mimic or suppressed by the relative miR inhibitor) microRNAs on myxoma-derived CSCs at P12. (B) Cellular growth curve in vitro shows that
miR-126-3p suppression by Lenti-miR-126-3p inhibitor-GFP infection increases myxoma-derived CSC proliferation in vitro as compared to control
(GFP) lentiviral infection at P12. (C) Graph showing the effects of the different indicated microRNA modulations on the clonogenic capacity of myx-
oma-derivedCSCs at P12. (D) Heat maps showing qRT-PCR analysis of GATA-4, NKX2.5, MEF2C, MYH6, MYH7, ACTC1 and TNNT2 gene transcripts
in differentiating myxoma-derived CSCs infected with the indicated Lenti-MiR or control Lenti-GFP after 14 days in cardiomyogenic media in vitro.
Colour scale indicates change in Ct (threshold cycle) relative to the normalized GAPDH control. (E) qRT-PCR data showing the expression levels of
the indicated cardiac genes in myxoma-derived CSCs infected with Lenti-miR-335-5p-Inhibitor after 14 days in in cardiomyogenic media in vitro. Data
are presented as fold induction over respective baseline values (Base). All data were obtained from myxoma-derived CSCs from three different
patients, where each CSC line was infected with the different indicated Lentiviral vectors. Each experiment for each CSC line was performed in tripli-
cate. Thus, the data in each panel is representative of nine biological replicates.
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Figure 7 c-kitpos/CD45neg/CD31neg myxoma-derived CSCs seed myxoma tumours in vivo. (A) Schematic representation of the design of the in vivo
myxoma tumours seeding study in NOD-SCID immunodeficient mice transplanted with myxoma-derived CSCs (from three different myxoma) at
different doses. Human CSCs (hCSCs) isolated from normal cardiac tissues (n = 3) were used as control (control hCSCs). In brief, after tissue dissoci-
ation, isolated cardiac cells were depleted of CD45pos and CD31pos cells then were enriched for c-kitpos cardiac cells through MACS immunolabel-
ling. Cells were kept in culture, cloned and engineered to express green fluorescent protein (GFP) by relative lentiviral transduction. GFPpos
myxoma-derived CSCs and GFPpos normal human CSCs were transplanted into the quadriceps muscle of NOD-SCID immunodeficient mice at
three different cell doses. (B) Representative Alcian Blue-PAS staining of the typical myxoma matrix with scattered cells formed by myxoma CSC
transplantation within mouse skeletal muscle. Scale bar = 75 lm. (C) GFPpos myxoma-derived CSCs and GFPpos control hCSCs were transplanted
in NOD-SCID immunodeficient mice at three different concentration. Myxoma tumour tissue formation was only detected in mice injected with
GFPposmyxoma-derived CSCs in a dose dependent manner (n = 27 NOD-SCID immunodeficient mice transplanted with GFPpos Myxoma-derived
CSCs). No histological detectable tumour tissue or mass at any injected cell number was detected after GFPpos normal human CSCs transplantation
(n = 18 NOD-SCID immunodeficient mice transplanted with GFPpos control hCSCs). (D) Picture of one of the only two visible and palpable myxoid
matrix mass in NOD-SCID immunodeficient mice injected with 106 GFPpos myxoma-derived CSCs. (E and F) Representative confocal images show-
ing scattered GFPpos myxoma-derived CSCs within the myxoid matrix (E, Chon Sulf immunostaining, red) grown out of the transplanted GFPpos
myxoma-derived CSCs. Most of these GFPpos cells were calretinin positive (F) showing that transplanted myxoma-derived CSCs differentiated in vivo
in the typical myxoma ‘leipidic’ cells (GFP/green, Calretinin/red, nuclei/DAPI/blue). Scale bar = 150 lm (E, F), 75 lm (F). (G) Representative image of
a NOD-SCID immunodeficient mouse showing no detectable or palpable tumour mass after GFPpos control normal hCSCs transplantation.




















































..Histologically, appearance of myxoma tumour tissue identified by
Alcian Blue-PAS staining with the typical myxoma matrix with scat-
tered cells, was directly proportional to the transplanted cell number
(Figure 7B and C). However, palpable masses were evident only in
two out of nine mice at 36 weeks after injection of 106 cells
(Figure 7D). Importantly, scattered cells within the formed myxoid
matrix stained positive for GFP, establishing their derivation from the
injected myxoma-derived c-kitpos/CD45neg/CD31neg CSCs
(Figure 7E). Most of these GFP cells (68 ± 5%) co-stained for
Calretinin (Figure 7F), showing that myxoma-derived c-kitpos/
CD45neg/CD31neg CSCs differentiated in the typical myxoma ‘leipi-
dic’ cells in vivo. In striking contrast, the c-kitpos/CD45neg/CD31neg
hCSCs from the normal controls were unable to form any
palpable mass or any histological detectable tumour in any of the
injected mice, independently of the cell number administered (Figure
7C and G).
Overall, the data presented in this study was strongly supportive
of the notion that the myxoma-derived c-kitpos/CD45neg/CD31neg
multipotent cells are closely related (derived from?) the myocardial
CSCs and that they are the ‘tumour-initiating cells’ of the myxoma.
The results of the transplantation of these cells into immunosup-
pressed mice further support this notion and clearly show that these
myxoma-derived c-kitpos/CD45neg/CD31neg CSCs seed de novo myx-
oma tumours in vivo (Take home figure).
Discussion
Data on mammalian and especially human cardiac neoplasias is very
scarce because the myocardium is a privileged tissue which for still
unknown reasons very rarely develops cancer. Therefore,
information about the pathogenesis of heart neoplasias is particularly
valuable to further understand its resistance to neoplastic transform-
ation and the potential origin of those rare appearances. The main
findings of the present study are: (i) c-kitpos/CD45neg/CD31neg cells,
which are the characteristic phenotype of the multipotent CSCs, are
present within atrial myxomas and fulfill all the criteria expected for
‘myxoma initiating/stem cells’; (ii) The myxoma-derived c-kitpos/
CD45neg/CD31neg multipotent cell exhibit a transcriptome and
miRNA network which is similar to that of the CSCs from normal
myocardium but with a relatively small fraction of dysregulated
mRNAs and miRNAs (miR-126-3p and miR-335, in particular)
involved in cell growth, differentiation and transformation pathways;
(iii) myxoma-derived initiating/stem cells in vitro and in vivo produce
the typical myxoid matrix; (iv) when transplanted into immunosup-
pressed mice, the myxoma-derived initiating/stem cells, in contrast to
the control CSCs, produce myxoma-like tumours with a polysac-
charide composition, calretinin expression, and cellular distribution
characteristic of the human atrial myxomas.
Cardiac myxoma is a relative rare and histologically benign gelatin-
ous mass, which despite its benignity has significant clinical relevance
due its common presentation.3 Indeed, myxomas can create life-
threatening haemodynamic instability, due the ability of the tumour
progressively or acutely to obstruct pulmonary or venous drainage,
to impair flow across the atrioventricular valves causing a filling de-
fect6,8 and/or embolism, due to tumour fragmentation, which typical-
ly cause cerebral embolism and transient/persistent neurological
dysfunction.6
While clinical course of cardiac myxomas has been very precisely
assessed, there is still considerable uncertainty as to their cell origin.
The tissue cell composition of myxomas is typically heterogeneous,
Take home figure The main findings of the study showing that cardiac myxomas arise from multipotent c-kitpos/CD45neg/CD31neg myxoma tu-
mour initiating cells and the working hypothesis of their direct derivation from normal c-kitpos/CD45neg/CD31neg cardiac stem/progenitor cells trans-
formed by specific miRNA modulation.






























































































with cells expressing protein markers specific to various cell lineages
including epithelial, endothelial, myogenic, myofibroblast, neural and
neuro-endocrine, often within the same mass.10
The presence of CSX cardiac homeobox transcripts on its own
suggested an endothelial derivation,7 while the detection of both
NKX2.5 and eHAND transcription factors within leipidic cells, sug-
gested a myogenic cell origin34 and variable expression of other
markers that suggest neural or neuro-endocrine origins.34 Therefore,
it has been suggested that most likely cardiac myxomas derive from a
pluripotent/multipotent mesenchymal stem cell or an endothelial
progenitor cell located around the fossa ovalis and surrounding
endocardium.10,34 Nevertheless, the precise nature of these putative
stem/progenitor cell is yet unknown.
Recently, the relevant role that cells with typical stemness proper-
ties play in the development of various cancer types has been pointed
out.49 These cells, like the stem cells of normal tissues, are character-
ized by their clonogenicity, multipotency, and self-renewal capacity.
Malignant cells exhibiting these properties have been then defined as
cancer stem cells (CaSCs) or tumour-initiating cells. Presumably, the
CaSCs originate from mutations in normal stem/progenitor cells
which when multiply with or without aborted differentiation induce
the formation and development of some primary tumours.
Independently, various research groups have shown a regenerative
process in the adult mammalian heart based, at least in part, on the
existence of CSCs which can be identified and harvested from human
heart tissues, as well as the different mammalian species
studied.19,21,50 Unfortunately, ongoing research on CSC biology and
regenerative potential has been jeopardized by recent scandals and
controversies.51,52 Moreover, several genetic cell-fate mapping stud-
ies in mice have claimed that endogenous regenerative potential of
CSCs is minimal.16,53,54 These cell-fate mapping studies have been
shown to fail to test the fate of the CSCs17,18,55,56 and, consequently,
the precise contribution of adult CSCs to endogenous cardiomyo-
cyte replacement in homeostasis or after injury remains controver-
sial. However, the evidence that myocardial tissue harbours cells
which in vitro and in vivo are self-renewing, clonogenic, and multipo-
tent showing CSC potential is uncontroverted.
On this basis, through cell and molecular characterizations of car-
diac myxoma tissue we have shown here that these tumours harbour
a cohort of c-kitpos/CD45neg/CD31neg cardiac cells. A cell type which
in normal mammalian tissue is highly enriched for CSCs.21 In myxo-
mas, these cells are characterized by the expression of transcription
factors and proteins typical of both cardiac progenitor as well as dif-
ferentiated cardiac lineages. In addition, a small fraction of these cells
within or isolated from the myxoma mass also express calretinin, a
neuronal marker, which is highly expressed in polygonal myxoma
cells.34 Furthermore, at early passages, the c-kitpos/CD45neg/CD31neg
myxoma-derived CSCs possess proliferative and clonogenic capacity
similar to normal human CSCs. However, myxoma-derived CSCs,
while secreting the typical mucopolysaccharides that compose the
myxoma gelatinous mass in vivo,34 progressively lose their self-
renewal capability and accumulate cell-cycle retardation and
increased apoptotic rate through increasing passages in vitro. In add-
ition, myxoma-derived CSCs exhibit an abortive differentiation po-
tential in vitro whereby they undergo a multi-linage differentiation
programme failing to specify into definitive cardiac cell lineages.
Although hampered by the difficulty and limitation of working with
samples of human tissue which makes the data presented here mainly
descriptive and falling short of being able to establish direct cause–ef-
fect relationship(s) (as it is also the case for most work based on pri-
mary human tissue), our findings strongly point to c-kitpos/CD45neg/
CD31neg myxoma-derived CSCs as the progeny of the CSCs present
in the normal myocardium and as the initiating/stem cell of cardiac
myxomas which in addition to their gelatinous structure are charac-
terized by a low proliferative index and the presence of a heteroge-
neous abortively differentiated cell phenotypes. This conclusion is
further strengthened by the fact that xenotransplantation of c-kitpos/
CD45neg/CD31neg myxoma-derived cells into immunodeficient mice
seed the formation and growth of myxoma in vivo, highly suggesting
that these cells are myxoma-initiating/stem cells.
Finally, from a clinical perspective, diagnosis of a cardiac myxoma is
standardly obtained by advanced cardiac imaging57,58. Surrogate bio-
markers (like circulating microRNAs)59 may help to optimize even at
early stages the diagnosis and treatment modalities. Therefore, it
remains highly tempting to speculate that miR-126 up-regulation in
myxoma initiating CSCs, as detected here, could indeed represent a
highly valuable serum biomarker for developing myxoma tumours. In
addition, although surgical removal of the tumour mass is a curative
therapy, in the cases of myxoma relapses, local administration of spe-
cific miR mimics/inhibitors (see Figure 6) to locally target c-kitpos/
CD45 neg/CD31neg myxoma tumour initiating cells could be theoret-
ically envisioned as a specific therapy for myxoma recurrences.
Conclusions
Overall, our findings strongly support the hypothesis that cardiac
myxomas are a stem cell-derived tumour arising from mesenchymal
multipotent resident CSCs. Thus, it is proposed that atrial myxomas
are a CSC-derived cardiac disease.
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Supplementary material is available at European Heart Journal online.
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Stirparo GG, Papait R, Scarfò M, Agosti V, Viglietto G, Condorelli G, Indolfi C,
Ottolenghi S, Torella D, Nadal-Ginard B. Adult c-kit(pos) cardiac stem cells are
necessary and sufficient for functional cardiac regeneration and repair. Cell 2013;
154:827–842.
25. Sandstedt J, Jonsson M, Dellgren G, Lindahl A, Jeppsson A, Asp J. Human C-
kitþCD45- cardiac stem cells are heterogeneous and display both cardiac and
endothelial commitment by single-cell qPCR analysis. Biochem Biophys Res
Commun 2014;443:234–238.
26. Ellison GM, Torella D, Karakikes I, Nadal-Ginard B. Myocyte death and renewal:
modern concepts of cardiac cellular homeostasis. Nat Clin Pract Cardiovasc Med
2007;4:S52–S59.
27. Torella D, Ellison GM, Karakikes I, Nadal-Ginard B. Resident cardiac stem cells.
Cell Mol Life Sci 2007;64:661–673.
28. Pucci A, Mattioli C, Matteucci M, Lorenzini D, Panvini F, Pacini S, Ippolito C,
Celiento M, De Martino A, Dolfi A, Belgio B, Bortolotti U, Basolo F, Bartoloni G.
Cell differentiation in cardiac myxomas: confocal microscopy and gene expres-
sion analysis after laser capture microdissection. Heart Vessels 2018;33:
1403–1410.
29. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to
cancer. Nat Rev Cancer 2003;3:895–902.
30. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res
2012;22:457–472.
31. Painter JT, Clayton NP, Herbert RA. Useful immunohistochemical markers of
tumor differentiation. Toxicol Pathol 2010;38:131–141.
32. Terracciano LM, Mhawech P, Suess K, D’Armiento M, Lehmann FS, Jundt G,
Moch H, Sauter G, Mihatsch MJ. Calretinin as a marker for cardiac myxoma.
Diagnostic and histogenetic considerations. Am J Clin Pathol 2000;114:754–759.
33. Deleyrolle LP, Ericksson G, Morrison BJ, Lopez JA, Burrage K, Burrage P, Vescovi
A, Rietze RL, Reynolds BA. Determination of somatic and cancer stem cell self-
renewing symmetric division rate using sphere assays. PLoS One 2011;6:e15844.
34. Singhal P, Luk A, Rao V, Butany J. Molecular basis of cardiac myxomas. Int J Mol
Sci 2014;15:1315–1337.
35. Graadt van Roggen JF, Hogendoorn PC, Fletcher CD. Myxoid tumours of soft
tissue. Histopathology 1999;35:291–312.
36. Miller DV, Tazelaar HD, Handy JR, Young DA, Hernandez JC. Thymoma arising
within cardiac myxoma. Am J Surg Pathol 2005;29:1208–1213.
37. Lam RMY, Hawkins ET, Roszka J. Cardiac myxoma: histochemical and ultrastruc-
tural localization of glycosaminoglycans and proteoglycans. Ultrastruct Pathol
1984;6:69–81.
38. Hao J, Zhao S, Zhang Y, Zhao Z, Ye R, Wen J, Li J. Emerging role of microRNAs
in cancer and cancer stem cells. J Cell Biochem 2014;115:605–610.
39. Zhang H, Zhang H, Zhao M, Lv Z, Zhang X, Qin X, Wang H, Wang S, Su J, Lv X,
Liu H, Du W, Zhou W, Chen X, Fei K. MiR-138 inhibits tumor growth through
repression of EZH2 in non-small cell lung cancer. Cell Physiol Biochem 2013;31:
56–65.
40. Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z, Liu R, Tang A, Li X, Liu F, Shen S. The
tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget
2016;7:45370–45384.
41. Yang D, Lutter D, Burtscher I, Uetzmann L, Theis FJ, Lickert H. miR-335 pro-
motes mesendodermal lineage segregation and shapes a transcription factor gra-
dient in the endoderm. Development 2014;141:514–525.
42. Cao J, Cai J, Huang D, Han Q, Yang Q, Li T, Ding H, Wang Z. miR-335 repre-
sents an invasion suppressor gene in ovarian cancer by targeting Bcl-w. Oncol Rep
2013;30:701–706.
43. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG,
Stainier DYR, Srivastava D. miR-126 regulates angiogenic signaling and vascular
integrity. Dev Cell 2008;15:272–284.
44. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA,
Bassel-Duby R, Olson EN. The endothelial-specific microRNA miR-126 governs
vascular integrity and angiogenesis. Dev Cell 2008;15:261–271.
45. Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S,
Bhatt D, Alder H, Marcucci G, Calin GA, Liu C-G, Bloomfield CD, Andreeff M,
Croce CM. MicroRNA fingerprints during human megakaryocytopoiesis. Proc
Natl Acad Sci USA 2006;103:5078–5083.
46. Meister J, Schmidt M. miR-126 and miR-126*: new players in cancer. Sci World J
2010;10:2090–2100.
47. Yu W, Goncalves KA, Li S, Kishikawa H, Sun G, Yang H, Vanli N, Wu Y, Jiang Y,
Hu MG, Friedel RH, Hu G-F. Plexin-B2 mediates physiologic and pathologic func-
tions of angiogenin. Cell 2017;171:849–864.e25.
48. O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of
initiating tumour growth in immunodeficient mice. Nature 2007;445:106–110.
49. Visvader JE. Cells of origin in cancer. Nature 2011;469:314–322.
50. Torella D, Ellison GM, Méndez-Ferrer S, Ibanez B, Nadal-Ginard B. Resident
human cardiac stem cells: role in cardiac cellular homeostasis and potential for
myocardial regeneration. Nat Clin Pract Cardiovasc Med 2006;3:S8–S13.
51. Davis DR. Cardiac stem cells in the post-Anversa era. Eur Heart J 2019;40:
1039–1041.
52. Chien KR, Frisén J, Fritsche-Danielson R, Melton DA, Murry CE, Weissman IL.
Regenerating the field of cardiovascular cell therapy. Nat Biotechnol 2019;37:
232–237.
53. Vagnozzi RJ, Sargent MA, Lin S-C, Palpant NJ, Murry CE, Molkentin JD. Genetic
lineage tracing of Sca-1þ cells reveals endothelial but not myogenic contribution
to the murine heart. Circulation 2018;138:2931–2939.



















..54. He L, Li Y, Li Y, Pu W, Huang X, Tian X, Wang Y, Zhang H, Liu Q, Zhang L,
Zhao H, Tang J, Ji H, Cai D, Han Z, Han Z, Nie Y, Hu S, Wang Q-D, Sun R, Fei J,
Wang F, Chen T, Yan Y, Huang H, Pu WT, Zhou B. Enhancing the precision of
genetic lineage tracing using dual recombinases. Nat Med 2017;23:1488–1498.
55. Vicinanza C, Aquila I, Cianflone E, Scalise M, Marino F, Mancuso T, Fumagalli F,
Giovannone ED, Cristiano F, Iaccino E, Marotta P, Torella A, Latini R, Agosti V,
Veltri P, Urbanek K, Isidori AM, Saur D, Indolfi C, Nadal-Ginard B, Torella D.
Kitcre knock-in mice fail to fate-map cardiac stem cells. Nature 2018;555:E1–E5.
56. Cianflone E, Torella M, Chimenti C, De Angelis A, Beltrami A P, Urbanek K,
Rota M, Torella D. Adult cardiac stem cell aging: a reversible stochastic phenom-
enon? Oxid Med Cell Longev 2019;2019:5813147 10.1155/2019/5813147PMC:
30881594.
57. Maleszewski JJ, Bois MC, Bois JP, Young PM, Stulak JM, Klarich KW. Neoplasia
and the heart. J Am Coll Cardiol 2018;72:202–227.
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